Sawai Pharma to acquire Upsher-Smith's generic drug unit for $1B

Japanese drugmaker Sawai Pharmaceutical Co., will purchase Minneapolis-based Upsher Smith's generic drug business for $1 billion, reports Bloomberg.

The acquisition marks Sawai's first overseas acquisition in the company's 88-year history, according to the report.

"Upsher-Smith has a very good eye on selecting products and pricing them to a level [that] can bring sufficient profit to the company," Sawai President Mitsuo Sawai told Bloomberg. "We have manufacturing technology that enables us to bring down cost and want to combine it."

Upsher-Smith's non-generic business is not included in the deal, which is expected to close next month.

More articles on supply chain:

Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Novartis receives expanded approval for lung cancer drug

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like